Progenics Pharmaceuticals Sets Third Quarter Financial Results Conference Call for November 11

company logo

TARRYTOWN, N.Y., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced that it will host a conference call and webcast to review third quarter financial results on Monday, November 11, at 8:30 a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 92604931. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available there for two weeks.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform includes an antibody-drug conjugate therapeutic and a small molecule targeted imaging agent, both in Phase 2 clinical trials. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra, an ultra-orphan radiotherapy candidate in phase 2 under an SPA. Progenics' first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is developing Relistor in Japan. Please visit us at www.progenics.com.

(PGNX-F)

CONTACT: Kathleen Fredriksen Corporate Development (914) 789-2871 kfredriksen@progenics.com

Source:Progenics Pharmaceuticals Inc.